Pain-relieving Endometriosis treatment will NOT be rolled out on the NHS, despite getting approval last week By Luke Chafer Published: 20:53 EDT, 7 September 2024 | Updated: 20:58 EDT, 7 September 2024 e-mail View comments A treatment for endometriosis will not be rolled out on the NHS despite getting approval for use in the UK last week. The new pill, a combination of the drugs relugolix, oestradiol and norethisterone acetate, has been shown to dramatically reduce the disease's painful symptoms. Endometriosis occurs when the uterine lining grows outside of the uterus itself, and affects one in ten women in the UK.
Patients in the UK wait, on average, more than eight years from the onset of symptoms to get a diagnosis. The new daily tablet reduces levels of the female sex hormone oestrogen and progesterone. Endometriosis occurs when the uterine lining grows outside of the uterus itself, and affects one in ten women in the UK (stock image) A study from 2022, published in The Lancet, found that 75 per cent of women on the new combo reported having reduced pain.
Read More My lungs collapse every time I have a period However, earlier this year the NHS spending watchdog, the National Institute for Health and Care Excellence (NICE), said it would not offer it to the 78,000 women in the UK living with endometriosis. It argued there is not evidence to show that the drug combo is more effective than existing treatments. Currently, endometriosis patients typically receive anti-inflamma.